Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 10/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 9/20 | 0.35 |
| ▸ | PPARA | Q07869 | 6/20 | 0.35 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BCR | P11274 | 1/20 | 0.33 |
| ▸ | RXFP2 | Q8WXD0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652592 | 0.89 | PPARG (0.35) | AURKAPPARGNR1H4FGFR4LMNA | |
| SCHEMBL652230 | 0.88 | RXFP1 (0.42) | AURKAPPARGNR1H4PPARAFGFR4 | |
| SCHEMBL2914823 | 0.87 | AURKA (0.35) | AURKAPPARGNR1H4PPARAFGFR4 | |
| SCHEMBL2912953 | 0.86 | GPR35 (0.40) | FGFR4ALDH1A1HPGDL3MBTL1 | |
| SCHEMBL650431 | 0.86 | AURKA (0.54) | AURKAABL1BCR | |
| SCHEMBL653327 | 0.85 | AURKA (0.40) | AURKAFGFR4RXFP1LMNAL3MBTL1 | |
| SCHEMBL653328 | 0.85 | AURKA (0.38) | AURKAPPARGNR1H4PPARAFGFR4 | |
| SCHEMBL651489 | 0.85 | RXFP1 (0.47) | AURKAFGFR4RXFP1ALDH1A1 | |
| SCHEMBL4088217 | 0.84 | AURKA (0.51) | AURKAABL1BCR | |
| SCHEMBL651483 | 0.83 | EGLN1 (0.40) | AURKAPPARGNR1H4PPARAFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119641-B2 | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-21 | — | — | US | disclosed |
| US-8119641-B2 | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-21 | — | — | US | disclosed |
| US-8119641-B2 | 1H-furo[3,2-C]pyrazole compounds useful as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-21 | — | — | US | disclosed |
| EP-2051981-B1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-08-25 | — | — | EP | disclosed |
| EP-2051981-B1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-08-25 | — | — | EP | disclosed |
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-2051981-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2009-04-29 | — | — | EP | disclosed |
| WO-2007138017-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007138017-A1 | 1H-FURO[3,2-C] PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239924-A1 | 1H-FURO[3,2-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS | IGF1R, CDK1, CDK15 | AURKA 5/4885PPARG 2608/4885NR1H4 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.